Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.
) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 1.5%. By the end of trading, Shire fell $1.43 (-1.0%) to $136.36 on light volume. Throughout the day, 258,904 shares of Shire exchanged hands as compared to its average daily volume of 445,800 shares. The stock ranged in price between $135.90-$136.75 after having opened the day at $136.12 as compared to the previous trading day's close of $137.79. Other companies within the Drugs industry that declined today were:
), down 39.9%,
), down 16.0%,
), down 9.5% and
), down 8.8%.
- EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass
Shire plc, a biopharmaceutical company, researches, develops, manufactures, sells, and distributes pharmaceutical products. It operates in three segments: Specialty Pharmaceuticals (SP), Human Genetic Therapies (HGT), and Regenerative Medicine (RM). Shire has a market cap of $26.0 billion and is part of the health care sector. The company has a P/E ratio of 37.7, above the S&P 500 P/E ratio of 17.7. Shares are up 50.4% year to date as of the close of trading on Monday. Currently there are 10 analysts that rate Shire a buy, no analysts rate it a sell, and 2 rate it a hold.
TheStreet Ratings rates
. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.
- You can view the full Shire Ratings Report.
On the positive front,
), up 72.9%,
), up 29.8%,
), up 19.1% and
), up 13.2% , were all gainers within the drugs industry with
) being today's featured drugs industry leader.
- Use our drugs section to find industry-relevant news.
- Or find some new ideas from our top rated stocks lists.
For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
) while those bearish on the drugs industry could consider
- Find other investment ideas from our top rated ETFs lists.